Tessera Therapeutics has been awarded up to $41.3 million from ARPA‑H to support its EMBODY program aimed at engineering immune cells directly inside the body. The funding will accelerate development of Tessera’s in vivo CAR‑T constructs and associated delivery technologies. ARPA‑H’s award underscores federal interest in lowering cell‑therapy manufacturing complexity and broadening patient access to engineered immune therapies.